In our study, PXN-AS1 levels were significantly increased in bone marrow mononuclear cells from TKIs-resistant CML patients and in imatinib-resistant CML cell lines, and PXN-AS1 inhibition was proved to alleviate TKIs resistance of CML IR cells. Here, PXN is linked to chronic myelogenous leukemia, BCR-ABL1 positive.